Language: BG BG
nav.cta
← Back to results
Active (not recruiting) Phase 1 2022-503136-13-00

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

Phase 1 – testing safety in a small group of people
Conditions: various B-cell malignancies

Sponsor: Abbvie Deutschland GmbH & Co. KG

trial.available_in: БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 88 participants
Locations 4
Belgium (1)
France (1)
Germany (1)
Spain (1)
Technical details
Status
Active (not recruiting)
Phase
Phase 1
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
17.10.2023
Registry ID
2022-503136-13-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.